Post-approval studies (Phase 4)Ended earlyNCT04140409
What this trial is testing
Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation
Who this might be right for
Neuroendocrine TumorsCarcinoid Syndrome
Cliniques universitaires Saint-Luc- Université Catholique de Louvain 10